Perrigo CO PLC PRGO
We take great care to ensure that the data presented and summarized in this overview for PERRIGO Co plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRGO
View all-
Vanguard Group Inc Valley Forge, PA14.9MShares$445 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13.1MShares$390 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX6.91MShares$206 Million0.06% of portfolio
-
State Street Corp Boston, MA6.79MShares$203 Million0.01% of portfolio
-
Deprince Race & Zollo Inc Winter Park, FL3.49MShares$104 Million2.45% of portfolio
-
Cooke & Bieler LP3.47MShares$104 Million1.09% of portfolio
-
Davenport & CO LLC3.45MShares$103 Million0.71% of portfolio
-
Thompson Siegel & Walmsley LLC3.44MShares$103 Million1.71% of portfolio
-
Wolf Hill Capital Management, LP New York, NY3.06MShares$91.2 Million5.11% of portfolio
-
Slate Path Capital LP New York, NY2.85MShares$84.9 Million1.84% of portfolio
Latest Institutional Activity in PRGO
Top Purchases
Top Sells
About PRGO
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Transactions at PRGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Erica L Mann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-19.42%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Erica L Mann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+28.8%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.46%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.36%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-36.23%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+43.01%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Adriana Karaboutis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.76%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Adriana Karaboutis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.72%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Bradley A Alford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-10.46%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Bradley A Alford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+17.89%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Orlando D Ashford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,259
-25.05%
|
$157,770
$30.22 P/Share
|
May 15
2024
|
Orlando D Ashford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,955
+34.29%
|
$328,650
$30.22 P/Share
|
May 15
2024
|
Katherine C. Doyle Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-21.95%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Katherine C. Doyle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+31.37%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Donal O'Connor Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-14.17%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Donal O'Connor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+22.79%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Geoffrey M. Parker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-17.19%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+26.37%
|
$262,920
$30.22 P/Share
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-5.26%
|
$33,930
$29.69 P/Share
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,249
+9.18%
|
$65,221
$29.69 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 153K shares |
---|---|
Open market or private purchase | 56.4K shares |
Grant, award, or other acquisition | 57.2K shares |
Payment of exercise price or tax liability | 76.8K shares |
---|